[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 209
Citations 0
Comment & Response
June 2016

In Defense of Off-label Prescribing—Reply

Author Affiliations
  • 1Department of Pharmaceutical Economics and Policy, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences (MCPHS), Boston
  • 2Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
JAMA Intern Med. 2016;176(6):861-862. doi:10.1001/jamainternmed.2016.1406

In Reply Unscientific prescribing constitutes 4 of 5 off-label uses,13 and this unscientific prescribing has resulted in a 54% increased risk of adverse drug events compared with on-label uses.2 To crack down on unscientific prescribing, drug regulatory bodies need to demand strong scientific evidence from pharmaceutical companies to safeguard the public.

First Page Preview View Large
First page PDF preview
First page PDF preview